Current Data

U.S. Cannabis Spot Index down 0.7% at $1,153 per pound.

The simple average (non-volume weighted) price was nominally unchanged at $1,223 per pound, with 68% of transactions (one standard deviation) in the $414 to $2,031 per pound range. The average reported deal size declined to 3.1 pounds. In grams, the Spot price was $2.54, and the simple average price was $2.70.

The relative frequency of trades for indoor flower increased week-over-week, by 2%, while transactions involving greenhouse product saw a decline in this metric of the same proportion. Warehouse flower’s share of the total reported weight moved nationwide shrank slightly this week, by about 1%, with the relative volumes of greenhouse and outdoor product both expanding modestly, by less than 1% each. The relative stability of national Transaction Stats in recent weeks belies their diversity in the major state markets, illustrated below.

The U.S. Spot Index declined by 0.7% this week to settle at $1,153 per pound. The volume-weighted price for indoor flower, which had risen fairly steadily from mid-January, leveled off this week. On a state level, Colorado was the only one of the major Western markets to see an increase in its Spot rate, while Massachusetts was the only other state with a functioning adult-use market to see an increase in its overall going price, and a relatively small one at that. The national composite rate averaged $1,154 per pound for February, off nominally from January’s monthly mean of $1,157 per pound. In 2018, the U.S. Spot Index slipped by 4.8% from January to February, from $1,343 to $1,279 per pound. Of the major and secondary state markets, only prices in Oregon and Nevada are currently displaying behavior at least somewhat similar to observations from the first two months of 2018.    

The national volume-weighted price for flower to be sold in adult-use markets slipped this week on decreases in California, Oregon, Washington, Nevada, and Alaska. Declines in the medical market of Arizona pulled down the national price for product designated for registered patients recorded this week, even as numerous other smaller medical systems saw upticks.